NIPRO JMI Pharma successfully produced Favipiravir in the name of Fluvigan Tablets (Favipiravir 200 mg) for the treatment of COVID -19 patients.
Mr. Md. Mizanur Rahman, CEO of NIPRO JMI Pharma, reiterated that Fluvigan will only be supplied to the hospitals dedicated for treatment of COVID-19 patients and in special cases to the patients having prescriptions from specialist doctors as per the guidance of Directorate General of Drug Administration [DGDA]. It will not be supplied to retail pharmacies at this stage.
Worldwide several drugs are being tested against COVID-19 patients. Earlier this year Favipiravir is used in Wuhan of China for treatment of COVID-19 patients. Two Clinical Trials signify the benefit of using Favipiravir for treating COVID-19 patients at earlier stage of the disease.